(NASDAQ: PAHC) Phibro Animal Health's forecast annual revenue growth rate of 6.78% is not forecast to beat the US Drug Manufacturers - Specialty & Generic industry's average forecast revenue growth rate of 129.3%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 26.15%.
Phibro Animal Health's revenue in 2025 is $1,296,215,000.On average, 6 Wall Street analysts forecast PAHC's revenue for 2026 to be $60,314,008,704, with the lowest PAHC revenue forecast at $57,760,391,400, and the highest PAHC revenue forecast at $62,462,289,928. On average, 6 Wall Street analysts forecast PAHC's revenue for 2027 to be $62,219,088,280, with the lowest PAHC revenue forecast at $59,462,802,936, and the highest PAHC revenue forecast at $64,488,970,328.
In 2028, PAHC is forecast to generate $63,921,499,816 in revenue, with the lowest revenue forecast at $61,286,815,296 and the highest revenue forecast at $66,029,247,432.